Gilead Sciences (GILD) –
-
Gilead Sciences (GILD) Misses Q1 EPS by 288c
-
Gilead posts quarterly loss on acquisition charge, revenue rises 5%
-
Form 8-K GILEAD SCIENCES, INC. For: Apr 25
-
Gilead Sciences Announces First Quarter 2024 Financial Results
-
HSBC Upgrades Gilead Sciences (GILD) to Hold
-
Gilead Sciences (GILD) April weekly option implied volatility into quarter results
-
Gilead Sciences (GILD) PT Lowered to $75 at UBS
-
Truist Securities Assumes Gilead Sciences (GILD) at Hold
-
Gilead Sciences (GILD) PT Lowered to $80 at Morgan Stanley
-
Gilead Sciences to Release First Quarter 2024 Financial Results on Thursday, April 25, 2024
-
Form 4 GILEAD SCIENCES, INC. For: Apr 01 Filed by: Parsey Merdad
-
Nurix Therapeutics (NRIX) Announces Extension of Collaboration with Gilead Sciences (GILD)
-
Form 144 GILEAD SCIENCES, INC. Filed by: Parsey Merdad
-
Form 4 GILEAD SCIENCES, INC. For: Mar 28 Filed by: Lofton Kevin E
-
Form ARS GILEAD SCIENCES, INC. For: Dec 31
-
Form DEF 14A GILEAD SCIENCES, INC. For: May 08
-
Form DEFA14A GILEAD SCIENCES, INC.
-
FDA Expands Indication for Gilead's (GILD) Vemlidy to Treat Chronic HBV Infection in Pediatric Patients as Young as Six
-
FDA Expands Indication for Gilead's Vemlidy (Tenofovir Alafenamide) to Treat Chronic HBV Infection in Pediatric Patients as Young as Six
-
Xilio Therapeutics (XLO) Announces $11.3 Million Private Placement Equity Financing, License Agreement with Gilead (GILD)
-
Gilead Sciences (GILD) and Xilio (XLO) Enter Exclusive License Agreement for Tumor-Activated IL-12 Program
-
Gilead and Xilio Announce Exclusive License Agreement for Tumor-Activated IL-12 Program
-
Gilead (GILD) reduces 2024 earnings guidance after completing CymaBay takeover
-
Form 8-K GILEAD SCIENCES, INC. For: Mar 22
-
Gilead Sciences (GILD) Announces Completion of Acquisition of CymaBay (CBAY)
-
Gilead Sciences Announces Completion of Acquisition of CymaBay
-
Center for Disease Analysis Foundation Announces First Round of Grantees for the CDAF-Relink Grant
-
Form PRE 14A GILEAD SCIENCES, INC. For: May 08
-
BMO Capital Reiterates Outperform Rating on Gilead Sciences (GILD)
-
Gilead Sciences (GILD) Board Member Kevin Lofton to Retire
-
Form 8-K GILEAD SCIENCES, INC. For: Mar 10
-
Form 4 GILEAD SCIENCES, INC. For: Mar 10 Filed by: Telman Deborah H
-
Form 4 GILEAD SCIENCES, INC. For: Mar 10 Filed by: Patterson Sandra
-
Form 4 GILEAD SCIENCES, INC. For: Mar 10 Filed by: Parsey Merdad
-
Form 4 GILEAD SCIENCES, INC. For: Mar 10 Filed by: O'Day Daniel Patrick
-
Form 4 GILEAD SCIENCES, INC. For: Mar 10 Filed by: Mercier Johanna
-
Form 4 GILEAD SCIENCES, INC. For: Mar 10 Filed by: Dickinson Andrew D
-
Gilead Sciences (GILD) Announces Expiration of Hart-Scott-Rodino Waiting Period for CymaBay (CBAY) Tender Offer
-
Gilead Sciences Announces Expiration of Hart-Scott-Rodino Waiting Period for CymaBay Tender Offer
-
Oppenheimer remain bullish on Gilead Sciences (GILD), HIV agents in 24/25 could provide conviction to investors
-
Gilead Sciences (GILD) and Merck (MRK) Report Phase 2 Data Showing an Investigational Oral Once-Weekly Combination Regimen of Islatravir and Lenacapavir Maintained Viral Suppression at Week 24
-
Gilead and Merck Announce Phase 2 Data Showing an Investigational Oral Once-Weekly Combination Regimen of Islatravir and Lenacapavir Maintained Viral Suppression at Week 24
-
Gilead Sciences (GILD), Merus (MRUS) Announce Collaboration to Discover Novel Antibody-Based Trispecific T-Cell Engagers
-
Gilead and Merus Announce Collaboration to Discover Novel Antibody-Based Trispecific T-Cell Engagers
-
Gilead Sciences (GILD) Reports New Real-World Data Supporting the Use of Veklury for People Hospitalized With COVID-19
-
New Real-World Data Further Support the Use of Veklury® (Remdesivir) for People Hospitalized With COVID-19
-
Gilead Sciences (GILD) HIV Treatment Research Pipeline Aims to Address Unmet Needs and Advance Public Health
-
Gilead’s Innovative HIV Treatment Research Pipeline Aims to Address Unmet Needs and Advance Public Health
-
RedHill Biopharma's (RDHL) Opaganib Selected for Evaluation by BARDA and NIH Countermeasures Programs
-
RedHill's Opaganib Selected for Evaluation by BARDA and NIH Countermeasures Programs
Back to GILD Stock Lookup